CRISPR: From Discovery To Clinic—And Charting A Path Forward
No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...
Hosted on MSN1d
CRISPR-Cas9 Off-Target Effects: Challenges and Solutions
The CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about ...
Q4 Earnings Surprise Greenlights CRISPR Therapeutics Stock Climb
CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...
Morocco World News4d
Gene Editing for Growth: How CRISPR Could Redefine Africa’s Agricultural Landscape
Africa is grappling with severe food insecurity in the wake of consecutive droughts, climate change, and ongoing conflicts, which are affecting millions across the continent.
Investing on MSN1d
CRISPR Therapeutics stock rises following analyst upgrade
Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.
Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...
Fintel on MSN1d
Evercore ISI Group Upgrades CRISPR Therapeutics (CRSP)
Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) ...
Research Analysts Set Expectations for CRSP Q3 Earnings
Brookline Capital Management issued their Q3 2025 earnings estimates for shares of CRISPR Therapeutics in a report released ...
Impacts5d
Unveiling the Power of CRISPR Screening in Modern Genomics
CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...